Korro Bio Inc (KRRO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KRRO Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Korro Bio Inc adapts its cash strategy across cycles.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
6 Months
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-38.54
Depreciation & amortization0.75
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.03
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation8.33
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Deferred Lease Incentives-
Increase Decrease In Deferred Financing Costs And Other Assets-
Increase Decrease In Royalties Payable Excluding Accounts Payable-
Increase Decrease In Contract With Customer Liability-
Non Cash Lease Expenses0.24
Increase Decrease In Lease Liabilities-0.60
Increase Decrease In Lease Liabilities-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.97
Increase (Decrease) in Accounts Payable1.95
Increase (Decrease) in Accrued Liabilities-2.52
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.35
Other Working Capital-0.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.41
Discontinued operations0.00
Net Cash flow from Operating Activities-33.07
Investing Activities
Capital Expenditures-0.06
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities-75.08
Real Estate Investments0.00
Payment For Proceeds From Sale Of Available For Sale Securities Debt-
Proceeds From Payment For Property And Equipment-
Advance Payments For Property And Equipment Not Yet Received-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Maturities, Prepayments and Calls of Other Investments25.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-50.14
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock85.30
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations25.23
Capital Expenditures Incurred But Not Yet Paid-
Debt Conversion Converted Instrument Amount-
Non Cash Dividend On Cumulative Convertible Preferred Stock-
Conversion Of Stock Amount Issued-
Cash Acquired In Connection With The Reverse Recapitalization-
Payment Of Reverse Recapitalization Transaction Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities85.30
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-33.13
Total Cash Flow2.08
4 historic quarters locked

Sign in to unlock the full Korro Bio Inc cash flow history.

About Korro Bio Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-336707

Figures are derived from filed reports and may be restated. Historical data is subject to revision.